As Medicare standardises remote patient monitoring for chronic care, commercial insurers take a more cautious, condition-specific approach, with policy changes and billing nuances set to reshape care delivery from late 2025 onwards.
Remote patient monitoring has moved into a more complicated phase for private insurance. Medicare now treats it as a standard part of chronic care, but commercial insurers are taking a narrower, more selective approach, with major policy changes rolling out in late 2025 and early 2026. For care teams, that has turned coverage into a patient-by-patient question: not just whether remote monitoring is clinically useful, but whether a given plan will pay for it.
At the centre of that debate is outcomes. Tenovi’s updated overview says commercial payers rely heavily on medical policy committees that examine whether home monitoring changes what happens to patients. In practice, that means coverage tends to follow evidence showing fewer hospital days, better blood pressure control or safer follow-up after delivery. Where the data are weaker or more mixed, insurers are far less likely to broaden access.
The strongest support remains in heart failure and hypertension. The article points to the TIM-HF2 trial, published in The Lancet, which found that patients with heart failure who submitted daily readings to a telemedical centre spent fewer days in unplanned cardiovascular hospital care than those receiving usual treatment, and also had lower all-cause mortality. It also cites the 2025 AHA/ACC high blood pressure guideline, which gives home blood pressure monitoring a much larger role than the 2017 version and says it works best when readings are paired with education, telehealth advice and follow-up. A postpartum blood pressure trial at the University of Pennsylvania likewise showed that home monitoring with text reporting produced far better early reading capture than office-based follow-up, underscoring the value of remote monitoring in the high-risk days after delivery.
That evidence base helps explain the shape of current commercial policies. Aetna’s updated clinical bulletin now covers remote monitoring for heart failure, hypertension and diabetes, provided the patient uses an FDA-cleared device, the data are used to change the treatment plan and a qualified clinician orders and oversees the service. Cigna takes a similar condition-by-condition approach, but its covered list also includes chronic obstructive pulmonary disease, gestational diabetes and hypertensive disorders of pregnancy. Primary hypertension outside pregnancy is not included on that list, so clinicians are being urged to check the policy before enrolling patients.
UnitedHealthcare has taken a more restrictive path, but not in force yet. The insurer announced a policy in late 2025 that would have limited coverage to heart failure and hypertensive disorders of pregnancy across several lines of business, including Medicare Advantage, commercial, exchange and Medicaid plans. After pushback from providers and medical societies, it postponed implementation, and its January 2026 bulletin says the change remains on hold until further notice. For now, members under existing terms can continue to receive coverage for other chronic conditions, but the situation remains fluid.
Billing has also become more nuanced. CMS finalised two new RPM codes for 2026, designed to cover shorter monitoring periods and shorter treatment-management episodes, which should help patients who only need a few weeks of follow-up after discharge or medication changes. But commercial adoption is uneven. Tenovi notes that Aetna’s current policy still recognises only the original remote monitoring codes, while other plans have started to add the newer ones. That means the same monitoring programme may be billable under one plan and non-covered under another, even when the clinical scenario is nearly identical.
The broader lesson for care teams is that coverage checks now matter as much as clinical selection. Tenovi advises verifying the member’s plan, the medical policy and any employer-specific terms before starting a patient, matching the device to the condition, and documenting how the data changed care. The California Center for Connected Health Policy also shows how much state-level rules can matter: its policy summaries say RPM became a covered benefit in California from July 2025, and that later Medi-Cal reimbursement rules, effective July 2026, require ordering by a physician or other qualified health professional, documented consent and justification in the record. Across private and public plans alike, the direction is the same: insurers want proof that remote monitoring is not just collecting numbers, but improving care.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
